Tumor-targeted pH-sensitive manganese oxide nanoparticle for enhanced breast cancer detection using MRI

肿瘤靶向 pH 敏感氧化锰纳米颗粒用于增强 MRI 乳腺癌检测

基本信息

  • 批准号:
    10487424
  • 负责人:
  • 金额:
    $ 21.29万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-08-01 至 2023-06-30
  • 项目状态:
    已结题

项目摘要

Approximately 2.1 million women globally will be diagnosed with breast cancer each year and over 626,000 women will die because of it. Triple negative breast cancer (TNBC) is the most aggressive subtype, with the greatest potential to metastasize and recur despite treatment. Our long-term goal is to develop an innovative contrast agent for enhanced early detection of TNBC recurrence that will greatly reduce the false negatives and false positives associated with current breast imaging techniques. Magnetic resonance imaging (MRI) detects more breast cancers than mammography; however, false positive diagnoses remain high with MRI due to the standard contrast agent used (e.g. gadolinium chelate). Gadolinium chelates are non-targeted MRI contrast agents that always generate signal, which leads to the inability to accurately distinguish benign from malignant tumors. Our approach is drastically different. Herein, we will develop novel tumor-targeted pH-activatable manganese oxide (MnO) nanoparticles (NPs) for early and specific breast cancer MRI detection. MnO NPs present a targeting peptide that binds to underglycosylated mucin-1 (uMUC-1) overexpressed on breast cancer cells. MnO NPs will be endocytosed specifically by cancer cells and dissolved in low pH endosomes to release Mn2+ ions to initiate MRI signal. Unlike conventional MRI, our targeted MnO NPs will specifically detect malignant tumors but not benign tumors, as uMUC-1 is only present on breast cancer cells. By reducing false positives, our approach will avoid unnecessary biopsies, surgery, further imaging, anxiety, and save up to $3 billion in medical bills annually. In addition, MnO NPs can promote detection of smaller tumors, as Mn2+ has higher relaxivity than gadolinium chelates and NPs can deliver more Mn2+ to the cancer site. Due to earlier diagnosis and prompt treatment enabled with our detection strategy, patient survival will be significantly increased. We hypothesize that uMUC-1 targeted pH-activatable MnO NPs will specifically label malignant breast tumors expressing uMUC-1 in vivo and produce sufficient MRI contrast to visualize smaller tumors than conventional gadolinium chelates. We will test this hypothesis with the following aims: 1) Design targeted pH-activatable MnO NPs to preferentially accumulate within TNBC tumors expressing uMUC-1 in vivo. 2) Determine degree of toxicity and biodistribution of targeted MnO NPs. 3) Establish potential of targeted pHactivatable MnO NPs for detecting smaller TNBC tumors compared to Multi Hance.
每年全球约有210万女性被诊断患有乳腺癌 626,000名女性将因此死亡。三阴性乳腺癌(TNBC)是最具侵略性的亚型, 即使治疗也有很大的转移和复发的可能性。我们的长期目标是发展一个 用于增强TNBC复发的早期检测的创新造影剂,将大大降低假阳性率。 与当前乳腺成像技术相关的阴性和假阳性。 磁共振成像(MRI)比乳房X光检查检测出更多的乳腺癌;然而, 由于使用了标准造影剂(例如钆螯合物),MRI的阳性诊断率仍然很高。 钆螯合物是非靶向MRI造影剂,其总是产生信号,这导致 无法准确区分良性和恶性肿瘤。我们的方法完全不同。在此, 我们将开发新的肿瘤靶向pH可激活的氧化锰(MnO)纳米颗粒(NPs),用于早期 和特异性乳腺癌MRI检测。MnO NPs呈现结合至MnO NPs的靶向肽。 在乳腺癌细胞上过表达的低糖基化粘蛋白-1(uMUC-1)。MnO NPs将被内吞 特别是通过癌细胞并且溶解在低pH内体中以释放Mn 2+离子来引发MRI信号。 与常规MRI不同,我们的靶向MnO NPs将特异性检测恶性肿瘤,但不能检测良性肿瘤。 uMUC-1仅存在于乳腺癌细胞上。通过减少误报,我们的方法将 避免不必要的活检,手术,进一步成像,焦虑,并节省高达30亿美元的医疗费用 每年。此外,MnO NPs可以促进较小肿瘤的检测,因为Mn 2+具有比Mn 2+更高的弛豫率。 钆螯合物和NP可以将更多的Mn 2+递送到癌症部位。由于早期诊断和及时 通过我们的检测策略,患者的生存率将显著提高。 我们假设uMUC-1靶向的pH可激活MnO纳米颗粒将特异性标记恶性乳腺癌, 在体内表达uMUC-1的肿瘤,并产生足够的MRI对比,以显示比 常规钆螯合物。我们将测试这一假设与以下目标:1)设计目标 pH-可活化MnO NP优先在体内表达uMUC-1的TNBC肿瘤内积累。(二) 确定目标MnO NP的毒性程度和生物分布。3)确定靶向pH可激活的可能性 与Multi Hance相比,MnO NP用于检测较小的TNBC肿瘤。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Margaret Bennewitz其他文献

Margaret Bennewitz的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Margaret Bennewitz', 18)}}的其他基金

Finding NEMO's Switchable MRI Signal Using Microfluidic Tumor Models
使用微流控肿瘤模型寻找 NEMO 的可切换 MRI 信号
  • 批准号:
    10652001
  • 财政年份:
    2023
  • 资助金额:
    $ 21.29万
  • 项目类别:
Tumor-targeted pH-sensitive manganese oxide nanoparticle for enhanced breast cancer detection using MRI
肿瘤靶向 pH 敏感氧化锰纳米颗粒用于增强 MRI 乳腺癌检测
  • 批准号:
    10709272
  • 财政年份:
    2018
  • 资助金额:
    $ 21.29万
  • 项目类别:
Tumor-targeted pH-sensitive manganese oxide nanoparticle for enhanced breast cancer detection using MRI
肿瘤靶向 pH 敏感氧化锰纳米颗粒用于增强 MRI 乳腺癌检测
  • 批准号:
    10246798
  • 财政年份:
    2018
  • 资助金额:
    $ 21.29万
  • 项目类别:

相似海外基金

Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
  • 批准号:
    MR/X034690/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.29万
  • 项目类别:
    Fellowship
Clinitouch-360: A digital health platform enabling robust end-to-end care of patients in Primary Care with depression and anxiety
Clinitouch-360:数字健康平台,可为初级保健中的抑郁和焦虑患者提供强大的端到端护理
  • 批准号:
    10098274
  • 财政年份:
    2024
  • 资助金额:
    $ 21.29万
  • 项目类别:
    Collaborative R&D
Mental Health and Occupational Functioning in Nurses: An investigation of anxiety sensitivity and factors affecting future use of an mHealth intervention
护士的心理健康和职业功能:焦虑敏感性和影响未来使用移动健康干预措施的因素的调查
  • 批准号:
    10826673
  • 财政年份:
    2024
  • 资助金额:
    $ 21.29万
  • 项目类别:
Healthy Young Minds: co-producing a nature-based intervention with rural High School students to promote mental well-being and reduce anxiety
健康的年轻心灵:与农村高中生共同开展基于自然的干预措施,以促进心理健康并减少焦虑
  • 批准号:
    MR/Z503599/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.29万
  • 项目类别:
    Research Grant
Visual analysis system to detect and predict the signs of anxiety in healthcare
用于检测和预测医疗保健中焦虑迹象的视觉分析系统
  • 批准号:
    2902083
  • 财政年份:
    2024
  • 资助金额:
    $ 21.29万
  • 项目类别:
    Studentship
Using generative AI combined with immersive technology to treat anxiety disorders
利用生成式人工智能结合沉浸式技术治疗焦虑症
  • 批准号:
    10109165
  • 财政年份:
    2024
  • 资助金额:
    $ 21.29万
  • 项目类别:
    Launchpad
"Flashforward" imagery and anxiety in young adults: Risk mechanisms and intervention development
年轻人的“闪现”意象和焦虑:风险机制和干预措施的发展
  • 批准号:
    MR/Y009460/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.29万
  • 项目类别:
    Fellowship
How parents manage climate anxiety: coping and hoping for the whole family
父母如何应对气候焦虑:全家人的应对和希望
  • 批准号:
    DP230101928
  • 财政年份:
    2024
  • 资助金额:
    $ 21.29万
  • 项目类别:
    Discovery Projects
An innovative biofeedback enhanced adaptive extended reality (XR) device to reduce perinatal pain and anxiety during and after childbirth
一种创新的生物反馈增强型自适应扩展现实 (XR) 设备,可减少分娩期间和分娩后的围产期疼痛和焦虑
  • 批准号:
    10097862
  • 财政年份:
    2024
  • 资助金额:
    $ 21.29万
  • 项目类别:
    Collaborative R&D
Application name Phase Space - VR hypnotherapy as early intervention for anxiety in students and young people
应用程序名称 Phase Space - VR 催眠疗法作为学生和年轻人焦虑的早期干预
  • 批准号:
    10055011
  • 财政年份:
    2023
  • 资助金额:
    $ 21.29万
  • 项目类别:
    Collaborative R&D
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了